Study of Oral OSI-027 in Patients With Advanced Solid Tumours/Lymphoma
Summary
The primary objective of this study is to determine the maximum tolerated dose (MTD) and to establish the recommended phase 2 dose of oral OSI-027 when administered via 3 schedules in patients with advanced solid tumors or lymphoma, namely, intermittent, weekly, and continuous.
Study Design
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Conditions
Any Solid Tumor or Lymphoma
Intervention
Schedule 1, Schedule 2, Schedule 3
Location
Karmanos Cancer Institute
Detroit
Michigan
United States
48201
Status
Recruiting
Source
OSI Pharmaceuticals
Results (where available)
Links
- Source: http://clinicaltrials.gov/show/NCT00698243
- Information obtained from ClinicalTrials.gov on July 15, 2010
Medical and Biotech [MESH] Definitions
Reinforcement Schedule
A schedule prescribing when the subject is to be reinforced or rewarded in terms of temporal interval in psychological experiments. The schedule may be continuous or intermittent.
Immunization Schedule
Schedule giving optimum times usually for primary and/or secondary immunization.
Drug Administration Schedule
Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience.
Mental Status Schedule
Standardized clinical interview used to assess current psychopathology by scaling patient responses to the questions.
Work Schedule Tolerance
Physiological or psychological effects of periods of work which may be fixed or flexible such as flexitime, work shifts, and rotating shifts.
Clinical Trials
A Dose and Schedule Finding Trial With AMG 531 for CIT in Adults With Lymphoma
The purpose of this study is to identify a well-tolerated, effective dose and schedule of AMG 531 for the treatment of CIT in subjects with lymphoma receiving multi-cycle chemotherapy.
Study of Inactivated Poliovirus Vaccine Given at an Earlier Schedule With Shorter Intervals
The purpose of this study was to evaluated the effectiveness of inactivated poliovirus vaccine at a vaccine schedule that is commonly used in developing countries. The effectiveness of in...
Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial
The purpose of the study is to evaluate the relative efficacy and safety of treatment of neovascular AMD with Lucentis on a fixed schedule, Avastin on a fixed schedule, Lucentis on a varia...
Flavopiridol to Treat Relapsed Mantle Cell Lymphoma or Diffuse Large B-Cell Lymphoma
Background: Mantle cell lymphoma (MCL) and diffuse large B-cell lymphoma (DLBCL) are aggressive subtypes of non-Hodgkin lymphoma. Flavopiridol is an investigational drug that works...
Twinrix Alternative Schedule Study
To compare the efficiency of protection against hepatitis-B virus by administration of the combined vaccine against hepatitis A and B using the schedule 0-1-12 months against the schedule...
PubMed Articles
PURPOSE: The primary objective of this phase I dose-escalation study was to identify the maximum tolerated dose (MTD) of sunitinib plus pemetrexed in patients with advanced cance...
A phase I study of sunitinib combined with modified FOLFOX6 in patients with advanced solid tumors.
PURPOSE: This phase I study assessed the safety, tolerability, maximum tolerated dose (MTD), pharmacokinetics, and preliminary antitumor effects of sunitinib combined with modified FOLFOX6 (mFOLFOX6)....
Background Sunitinib is an oral multitargeted tyrosine kinase inhibitor of vascular endothelial growth factor and platelet-derived growth factor receptors, as well as of other receptor types. We have...
Previous studies have shown that the dual phosphatidylinositide 3-kinase/mammalian target of rapamycin (PI3K/mTOR) inhibitor NVP-BEZ235 radiosensitizes tumor cells if added shortly before ionizing rad...
PURPOSE: To investigate the pharmacological effects of different erlotinib (ER) and gemcitabine (GM) combination schedules by in vitro and in vivo experiments and PK/PD models in non-small cell lung c...
